| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 23, 2026 | Zai Lab Raises $250 Million PIPE To Advance DLL3-Targeting ADC Zocilurtatug Pelitecan | Zai Lab has entered into an agreement to raise approximately $250 million through a private investment in public equity financing, with proceeds primarily earmarked for the global development of its DLL3-targeting antibody-drug conjugate zo... |
| Oct 10, 2026 | Atrium Therapeutics Raises $50 Million Private Placement To Advance Precision Cardiology Pipeline | Atrium Therapeutics entered into a securities purchase agreement with institutional investors for a $50 million private placement to support development of its precision cardiology pipeline.
Investors participating in the financing include ... |
| Oct 2, 2026 | Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s | Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes, either as independent treatments or layered on top of existing drugs.
A new slate of injections, pills, and ... |
| Aug 28, 2026 | Kazia Therapeutics Limited Announces Proposed Public Offering | SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restor... |
| Aug 28, 2026 | Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering | SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restor... |
| Aug 19, 2026 | Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock more than doubles | An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial.
The combination regimen met the main study goal of significantly extending the time patients lived withou... |
| Aug 7, 2026 | Shares of this digital medical platform jumped more than 100% overnight. Here’s why | Doximity had a solid first quarter and raised its full year revenue guidance.
But AI search isn’t baked into these forecasts, analysts believe, and it’s bringing in 10 times the revenue it costs to run, the CEO revealed on the conference ca... |
| Jul 15, 2026 | Bambusa Therapeutics Appoints Howard Liang, Ph.D. to its Board of Directors and Establishes Scientific Advisory Board | Dr. Liang brings deep biopharma finance, strategy, and capital markets expertise to support the company's next phase of growth
Bambusa also forms a Scientific Advisory Board of globally recognized leaders in biopharma, dermatology, and... |
| Jul 12, 2026 | AstraZeneca's Pipeline Premium Challenged After Wainua Trial Failure | AstraZeneca faced a rare clinical failure with its Wainua drug in a late-stage trial for ATTR cardiomyopathy. Shares plunged significantly, well beyond the drug's estimated financial impact. This event challenges the pharmaceutical gia... |
| Jul 11, 2026 | AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable? | AstraZeneca posted a rare clinical trial failure on Thursday, sending shares down 6% to their worst day in over two years.
Analysts estimate the trial miss wiped just 2-4% from their valuation models but the market reaction suggested it was... |
| Jul 7, 2026 | Vicore Pharma to Participate in the Leerink Therapeutics Forum | STOCKHOLM, SE / ACCESS Newswire / July 7, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor ago... |
| Jun 30, 2026 | Medicare will start covering obesity drugs for the first time. Here’s what patients should know | Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a copay of just $50 per month through a temporary program called Bridge.
The move could unlock a vast new patient population for Novo Nordisk and... |
| Jun 29, 2026 | uniQure Closes Upsized $259 Million Public Offering | uniQure announced the closing of its previously announced upsized underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share.
The offering included 741,758 ordinary shares issued after the under... |
| Jun 28, 2026 | Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet | Millions of older Americans in Medicare are about to gain access to obesity drugs through Medicare’s new Bridge demonstration program for a monthly copay of just $50.
But many seniors may be unaware of the landmark shift starting on July 1,... |
| Jun 25, 2026 | Definium Therapeutics Prices Upsized $700 Million Public Offering | Definium Therapeutics announced the pricing of an upsized underwritten public offering of 20,588,236 common shares at a public offering price of $34 per share.
The gross proceeds to Definium from the offering, before deducting underwriting ... |
| Jun 14, 2026 | Parabilis Medicines Closes Upsized IPO And Raises More Than $845 Million Including Regeneron Private Placement | Parabilis Medicines, a clinical-stage biopharmaceutical company focused on developing therapies against historically undruggable protein targets, announced the closing of its upsized initial public offering and a concurrent private placemen... |
| May 31, 2026 | A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China | An experimental lung cancer drug from Akeso and Summit Therapeutics improved survival in the Harmoni-6 Phase 3 trial conducted in China, according to results being presented at the American Society of Clinical Oncology annual meeting.
Calle... |
| May 26, 2026 | Lilly goes on $20 billion buying spree as company seeks next act | Getting your Trinity Audio player ready...
By Madison Muller, Gerry Smith, Bloomberg News
Eli Lilly & Co. is on a record spending spree, announcing acquisitions worth more than $20 billion so far in 2026 as the drugmaker expands beyond ... |
| Mar 9, 2026 | AN2 Therapeutics: $40 Million Private Placement Financing Announced | AN2 Therapeutics announced that it has entered into a securities purchase agreement for a private placement expected to generate approximately $40 million in gross proceeds before deducting placement agent fees and other expenses. The finan... |
| Feb 26, 2026 | Honest Health: $140 Million Raised For Value-Based Care Expansion | Honest Health announced it has raised $140 million in a capital round led by NewSpring Healthcare, underscoring growing demand for its health system-focused approach to value-based care. The funding will support the company’s continued expa... |
| Feb 23, 2026 | Sensei Biotherapeutics Acquires Faeth Therapeutics And Raises $200 Million In Private Placement | Sensei Biotherapeutics announced it has acquired Faeth Therapeutics and secured approximately $200 million in gross proceeds through a concurrent private placement, positioning the combined company to advance its oncology pipeline through k... |
| Feb 6, 2026 | Hims & Hers shares tick lower after Novo’s legal threat | Online telehealth company Hims & Hers stock ticked lower Friday after Novo Nordisk said its newly announced Wegovy pill copy was illegal and that it would take legal action.
Hims is launching its pill for as little as $49, significantly... |
| Jan 16, 2026 | Novo Nordisk shares rise 8% after Wegovy obesity pill has ‘solid’ launch | Shares of Novo Nordisk rose more than 8% on Friday after early prescription data showed an encouraging start to the launch of the company’s new GLP-1 pill for obesity in the U.S.
In a Friday note, TD Cowen analysts called it a “solid start”... |
| Jan 9, 2026 | Real Chemistry Establishes RC Resolve, an Advisory Practice for Healthcare’s Most Critical Business, Regulatory and Value Inflection Points | Real Chemistry today announced the launch of RC Resolve, a healthcare advisory practice designed to help leaders navigate the value inflection points where science, business, economics, policy and risk management intersect. RC Resolve offer... |
| Dec 24, 2025 | Syremis Therapeutics Launches With $165 Million Series A Funding To Advance New Schizophrenia And Depression Drug Programs | Syremis Therapeutics, a clinical-stage biopharmaceutical company focused on mental health, has launched with $165 million in Series A financing to advance a neuropsychiatric pipeline rooted in clinically validated biology. The round was co-... |
| Dec 18, 2025 | Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound | Eli Lilly said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking Wegovy and Zepbound injections in a late-stage trial.
The company also said it has filed for... |
| Nov 2, 2025 | Where the blockbuster weight loss drug market stands today — and what’s coming next | The blockbuster weight loss drug market is entering a new chapter of growth.
Eli Lilly and Novo Nordisk are both focused on fighting for market share, ramping up supply, testing new uses for their medicines and bringing the next wave of obe... |
| Sep 21, 2025 | Lazard Hires Geoffrey Porges to Healthcare Advisory Group | Lazard has announced that Dr. Geoffrey Porges has joined the firm as a Managing Director within its Healthcare Advisory Group, where he will advise on transactions across the diversified biopharmaceutical sector. This appointment brings a s... |
| Sep 9, 2025 | Shares of this under-the-radar weight-loss drug play could double, says Leerink Partners | |
| Sep 8, 2025 | Stocks close at record highs despite job worries, looming inflation reports | All three major indexes closed at record highs Tuesday as investors moved past concerns about the state of the U.S. economy.
The S&P 500 index settled up 0.27% at 6,512.61, while the Nasdaq Composite gained 0.37% to end the day at 21,87... |
| Jul 31, 2025 | Pandemic darlings Moderna, BioNTech are now on two different paths | Covid-19 vaccine makers Moderna and BioNTech became household names almost overnight.
Moderna and BioNTech have spent their Covid vaccine windfalls differently, with Moderna investing in its own mRNA technology and BioNTech pursuing deals t... |
| Jan 25, 2025 | Medicare Drops Appeal in UnitedHealth Star Rating Lawsuit | (Bloomberg) -- US officials dropped their appeal of a UnitedHealth Group Inc. lawsuit challenging the federal Medicare program’s quality ratings, a potential boon for insurers protesting the rankings that drive billions of dollars in paymen... |
| Jun 12, 2024 | Leerink Partners Announces Addition of Evan Karp to Derivatives Team | BOSTON, June 12, 2024 /PRNewswire/ -- Leerink Partners, a leading investment bank specializing in healthcare, is pleased to announce the appointment of Evan Karp as Senior Managing Director, Derivatives. Mr. Karp will be based in the firm&#... |
| Jun 10, 2024 | WWDC 2024 Highlights: iOS 18 Brings Enhanced Privacy Controls to iPhone | By Quincy Jon
Published Jun 10, 2024 9:26PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard Share on Pocket
The Food and Drug Administration's (FDA) advisory committee endorsed Monday (June 1... |
| Jun 10, 2024 | Permira: Substantial Investment In PharmaCord Revealed | Global investment firm Permira and PharmaCord, a leading provider of patient services for the pharmaceutical industry, announced that a company backed by the Permira funds has signed a definitive agreement to make a substantial investment i... |
| May 24, 2024 | CVS reportedly seeks PE partner for Oak Street Health growth | figcaption>span]:font-sans">
CVS Health wants to find a private equity partner to back new Oak Street Health clinics, Bloomberg reports, citing sources familiar with the matter.
Why it matters: The move comes barely a year after ... |
| May 22, 2024 | Leerink Partners Adds Chris Scotti to Institutional Sales Team | BOSTON, May 22, 2024 /PRNewswire/ -- Leerink Partners, a leading investment bank specializing in healthcare, today announced the addition of Chris Scotti as Senior Managing Director, Institutional Sales. Mr. Scotti is based in the firm'... |
| Mar 25, 2024 | AbbVie Gets Another Ulcerative Colitis Contender via $137M Landos Acquisition | AbbVie already has blockbuster drugs for ulcerative colitis, but that isn’t stopping the pharmaceutical giant from trying to expand its scope in this disease. To that end, the company is acquiring Landos Biopharma, a clinical-stage biotech ... |
| Mar 8, 2024 | Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference | |
| Mar 8, 2024 | Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference | |
| Mar 6, 2024 | Apnimed to Participate in the Upcoming Leerink Partners Global Biopharma Conference | |
| Mar 6, 2024 | HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference | |
| Mar 6, 2024 | Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference | |
| Mar 6, 2024 | Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024 | |
| Mar 6, 2024 | Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024 | |
| Mar 6, 2024 | ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024 | |
| Mar 6, 2024 | Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference | |
| Mar 6, 2024 | ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference | |
| Mar 5, 2024 | Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024 | |
| Mar 5, 2024 | Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024 | |
| Mar 5, 2024 | Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference | |
| Mar 5, 2024 | Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024 | |
| Mar 5, 2024 | Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference | |
| Mar 5, 2024 | Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference | |
| Mar 5, 2024 | 89bio to Participate in the Leerink Partners Global Biopharma Conference | |
| Mar 5, 2024 | Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference | |
| Mar 5, 2024 | Opthea to Participate in the Leerink Partners Global Biopharma Conference | |
| Dec 18, 2023 | Biotechs end year 'trading for nothing' as investors mull 'what is IPO-able today?' | “It's been, I would say, probably one of the more challenging years of my professional career.” So says Joel Drewry, a principal investor at Versant Ventures who’s been white-knuckling the rollercoaster ride, or Tower of Terror, that’s... |
| Jan 9, 2019 | SVB Financial Group Acquires Leerink Holdings | SVB Financial Group (NASDAQ: SIVB), the parent company of Silicon Valley Bank, completed the acquisition of Leerink Holdings LLC, a Boston, MA-based parent company of healthcare and life science investment bank Leerink Partners.
The amount ... |
| Nov 14, 2018 | Term Sheet — Wednesday, November 14 | SOFTBANK
Good morning Term Sheet readers. This is Lucinda filling in for Polina until Friday. Please send all deals to [email protected].
Paid Content How can you protect what you can't see? From ExtraHop
That comes after Softba... |
| Jun 18, 2018 | Leerink Capital Appoints Karl Beinkampen as President | Leerink Capital Partners, a multi-strategy healthcare-focused principal investment business, announced today that Karl Beinkampen, CFA will join the firm in June as President, responsible for all aspects of LCP’s business and activities. Mr... |
| Dec 6, 2017 | Quanterix Corporation Announces Pricing of Initial Public Offering | LEXINGTON, Mass.–(BUSINESS WIRE)–December 7, 2017–
Quanterix Corporation, a company with a next generation, ultra-sensitive digital platform that advances precision health, today announced the pricing of its initial public offering of 4,275... |
| Oct 20, 2017 | Leerink’s Cozzens on New Health IT Fund, A.I.’s Future as a Platform | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Despite uncertainty over the future of the Affordable Care Act, investors continue to see opportunities to build successful businesses in healthcare technology and related ser... |
| Sep 29, 2017 | Leerink Transformation Partners Closes Maiden Fund, at $313M | Leerink Transformation Partners (LTP), a Boston, MA-based investor in innovative companies in the healthcare IT and services sectors, closed its maiden fund, at $313m.
Leerink Transformation Fund I LP focuses on growth equity investing in h... |
| Sep 28, 2017 | Leerink Transformation Partners Closes $313 Million Growth Equity Fund | BOSTON--(BUSINESS WIRE)--Leerink Transformation Partners (LTP) announced the formation of its inaugural fund – Leerink Transformation Fund I L.P. (LTF I) – with $313 million in assets under management, significantly oversubscribed versus th... |
| May 24, 2017 | Term Sheet — Wednesday, May 24 | ET CETERA
Purse purgatory: We’ve written about Coach’s increasing interest in M&A before. Today Fortune’s Phil Wahba published a feature on the company’s turnaround. The relevant part for Term Sheet readers:
Paid Content You can't ... |
| Apr 30, 2017 | Leerink Transformation Partners Raises $200.5M for Maiden Fund | Boston-based growth equity firm Leerink Transformation Partners has raised $200. 5 million for its inaugural fund, according to an SEC filing. The target is $250 million. LTP focuses on companies in the healthcare technology and services se... |
| Jun 2, 2016 | MA's Digital Health Initiative Announces a $26M Venture Fund, Reveals Fenway Incubator | On Wednesday, June 1, a group of Boston business backers announced a new venture fund for Massachusetts digital healthcare startups. The Massachusetts Innovation Catalyst Fund, totaling $25.8 million in assets, will support any stage ventur... |
| Jun 1, 2016 | Mass. Digital Health Initiative Unveils $26M Fund, Incubator Space | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Massachusetts digital healthcare startups will have more resources to tap into, thanks to a new $25.8 million venture fund and an incubator space near Fenway Park unveiled tod... |
| Sep 17, 2015 | Daily funding roundup - September 17, 2015 | HelloFresh raised $85M; Kyruus landed $25M; Typeform secured $15M
Advizr, a highly intuitive and automated financial planning application for advisors serving Gen X and Y clients, announces the close of another financing round and adds indu... |
| Jul 23, 2015 | Daily funding roundup - July 23, 2015 | Flipboard raised $50M; Notion Capital launched $120M; CarPrice closed $40M
CarPrice wants to be the company that brings the process of buying used cars in Russia online closed $40 million in Series B funding. The round was led by Baring Vos... |
| Aug 26, 2014 | Two AirStrip customers take part in $25M fundraise to move into home health market | Gary and Mary West Health Investment Fund, Sequoia Capital, and Wellcome Trust led the investment round. Leerink Partners also took part in the financing.
Update In a phone interview with MedCity News, Portela said this year it has been ram... |
| Apr 7, 2014 | Mobile Healthcare Startup Wellframe Raises $1.5M to Put a Nurse in Patients' Pockets | Boston-based mobile health care startup Wellframe announced Monday it has secured $1.5 million in seed funding. The startup's mobile platform enables outpatients with serious conditions to stay in close contact with their health care p... |
| Mar 1, 2012 | Lilly’s big gamble: Will a risky drug for Alzheimer’s offset losses from generics? | Meanwhile, a competitor’s Alzheimer’s candidate is at the same point in the clinical trial process. Analysts suggest that success with solanezumab could make a secure future for Lilly in the Alzheimer’s treatment market. A failure, on the o... |
| Aug 18, 2010 | Cancer drug developer Endocyte files for $86M IPO | Endocyte’s small-molecule drug conjugates “actively target receptors that are over-expressed on diseased cells,” the company said in its registration statement. This targeting enables patients to be treated with highly active drugs or high ... |
| Dec 18, 2009 | Analyst: Medical device sector should outperform in 2010 | Après le deluge, le bounce. Or at least a solid rebound for the medical device sector, according to analysts at New York investment firm Leerink Swann, who predict a rising tide that should lift most ships in the coming year.
In the firm’s ... |
| Jul 3, 2008 | Northstar Neuroscience Huddles to Consider Unsolicited Takeover Bid | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Northstar Neuroscience is in one tight spot. The Seattle-based medical device company’s lead product candidate for stroke patients failed in clinical trials on Jan. 22, and 83... |
| Two AirStrip customers take part in $25M fundraise to move into home health market | Updated AirStrip, a mobile health company that makes clinical data accessible on smartphones and other mobile devices, has raised $25 million in strategic capital, according to a company statement. The funding will help the company move int... |
| Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth | An established but promising group of cancer drugs was a red-hot market in 2023, and more acquisitions and advancements are expected in the year ahead.
That was one clear takeaway from the JPMorgan Healthcare Conference in San Francisco.
Re... |
| Lilly’s big gamble: Will a risky drug for Alzheimer’s offset losses from generics? | In the world of the pharma patent cliff, Eli Lilly & Co. (NYSE:LLY) stands in a particularly vulnerable spot.
As the drugmaker awaits clinical trial results from a late-stage Alzheimer’s candidate, company leaders are faced with reports... |
| Cancer drug developer Endocyte files for $86M IPO | West Lafayette, Indiana, biopharmaceutical company Endocyte Inc. hopes to raise more than $86 million from an initial public offering of stock.
The company that develops small-molecule drug “conjugates” to treat cancer and inflammatory dise... |